Group 1 - Halper Sadeh LLC is investigating iTeos Therapeutics, Inc. for potential violations related to its sale to Concentra Biosciences, LLC, which involves a cash offer of $10.047 per share and contingent value rights [1] - The contingent value rights include the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - WK Kellogg Co is being sold to The Ferrero Group for $23.00 per share in cash, prompting legal inquiries regarding shareholder rights [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Points - The proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC involves shareholders receiving $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - Kahn Swick & Foti, LLC is investigating whether the proposed transaction adequately values iTeos and the process leading to this valuation [1] Company and Industry Summary - iTeos Therapeutics, Inc. is currently in a proposed transaction to be acquired by Concentra Biosciences, LLC [1] - The investigation by Kahn Swick & Foti, LLC is focused on the adequacy of the transaction consideration and the valuation of the company [1][2] - The transaction is structured as a tender offer, indicating that timing is critical for stakeholders [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39401 iTeos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Dela ...

Core Viewpoint - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of iTeos Therapeutics, Inc. and ZimVie Inc. [1][2] Group 1: iTeos Therapeutics, Inc. - iTeos Therapeutics, Inc. is set to be acquired by Concentra Biosciences, LLC for $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the disposition of certain product candidates within six months post-closing [1] Group 2: ZimVie Inc. - ZimVie Inc. is being sold to an affiliate of ARCHIMED for $19.00 in cash per share [2] Group 3: Legal Actions and Shareholder Rights - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4]

NEW YORK, July 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors concerning the proposed acquisition of the company by Concentra Biosciences, LLC. Stockholders will receive $10.047 and one contingent value right for each share of iTeos Therapeutics stock that they hold. The transaction is expected to close in the third quarter of 2025.If you are a stockholder of iTeos Therapeutics, Inc. and are ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating iTeos Therapeutics, Inc. (NASDAQ: ITOS) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transact ...

Core Viewpoint - iTeos Therapeutics, Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire iTeos for $10.047 per share in cash, along with a contingent value right (CVR) [1][2][3] Group 1: Merger Agreement Details - The acquisition price includes $10.047 in cash per share of iTeos common stock and a CVR that entitles shareholders to 100% of iTeos' net cash exceeding $475 million and 80% of net proceeds from certain product candidates sold within six months post-closing [1][3] - The iTeos board of directors unanimously approved the merger, determining it to be in the best interests of all stockholders after a strategic review [2] - Concentra will initiate a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock, with the transaction expected to close in the third quarter of 2025, subject to customary closing conditions [3] Group 2: Conditions and Advisors - The closing of the offer is contingent upon the tender of shares representing at least a majority of outstanding shares and the availability of at least $475 million in cash at closing [3] - TD Cowen is serving as the exclusive financial advisor to iTeos, while Ropes & Gray LLP is providing legal counsel to iTeos, and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra [4]

Clinical Trial Data & Pipeline - iTeos anticipates multiple clinical data readouts in 2025, including data from GALAXIES Lung-201, GALAXIES H&N-202, TIG-006 H&N, and EOS-984 [2, 7] - GALAXIES Lung-201 Phase 2 trial showed an Objective Response Rate (ORR) of 633% with Belrestotug 100mg + Dostarlimab, 656% with Belrestotug 400mg + Dostarlimab, and 767% with Belrestotug 1000mg + Dostarlimab, compared to 375% with Dostarlimab alone [26] - In the GALAXIES Lung-201 trial, ctDNA analysis showed a median ctDNA % change of -94% in the Belrestotug 400mg + Dostarlimab cohort and -97% in the Belrestotug 1000mg + Dostarlimab cohort, compared to -65% with Dostarlimab alone [34] - The GALAXIES Lung-201 trial is enrolling 340 patients to evaluate Belrestotug + Dostarlimab safety, efficacy, PK/PD [18] - The GALAXIES H&N-202 trial is enrolling 360 patients to evaluate the antitumor activity and safety of Dostarlimab + novel IOs [46] - The company is enrolling 1000 patients in the GALAXIES Lung-301 Phase 3 trial to evaluate Belrestotug + Dostarlimab safety and efficacy vs placebo + pembrolizumab [42] - The company's TIGIT program has data readouts with >400 patients from TIGIT:PD-1 trials in 1L NSCLC and 1L HNSCC [51] - The company's EOS-984 Phase 1 trial is enrolling 84 patients to evaluate safety/tolerability of EOS-984 as a monotherapy and in combination with pembrolizumab [66] - The company's TRM-010 Phase 1 trial is enrolling 40 patients to evaluate safety/tolerability of EOS-215 as a monotherapy and in combination with pembrolizumab [82] Financial Status - iTeos had approximately $624 million in cash, cash equivalents, and short-term investments as of March 31, 2025, providing a cash runway through 2027 [6, 87] TIGIT Program & Differentiation - Belrestotug is the first and only TIGIT to demonstrate robust target engagement and Phase 1 monotherapy activity [15] - Belrestotug is the only TIGIT with proven Treg depletion at all doses [15]

Core Viewpoint - iTeos Therapeutics, Inc. (ITOS) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for iTeos Therapeutics suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, iTeos Therapeutics is expected to earn -$2.68 per share, reflecting a 19.3% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for iTeos Therapeutics has increased by 36.7%, indicating positive sentiment among analysts [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - The upgrade of iTeos Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - iTeos Therapeutics, Inc. intends to wind down its operations as part of a strategic review aimed at maximizing shareholder value through potential asset sales and leveraging its cash balance [2][3]. Group 1: Company Operations - The Board of Directors has decided to cease clinical and operational activities following a comprehensive assessment of the company's development pipeline and financial position [3]. - The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders [2][3]. Group 2: Company Background - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics, leveraging its expertise in tumor immunology [4].